Cannabis Law Report

DECEMBER 8, 2021

Global Psychiatry Partnering 2014 to 2021 provides the full collection of Psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Access to headline, upfront, milestone and royalty data. Access to hundreds of Psychiatry deal contract documents. Report Scope.

Access 40

Access Data Pharmaceutical Research and Development 40

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. The live webcast can be accessed here and on the investor page of Marinus’ website. About Marinus Pharmaceuticals.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

SEPTEMBER 2, 2022

The pharmaceutical industry takes a serious economic hit after states legalize marijuana—with an average market loss of nearly $10 billion for drugmakers per each legalization event—according to a first-of-its-kind study. By expanding access and, thus use, legalization could permit cannabis to compete with conventional pharmaceuticals.

Pharmaceutical 52

Pharmaceutical Legalization Marijuana Data 52

Cannabis Law Report

JUNE 5, 2021

” Kulfas’ presentation began with some hard data, giving an account of the importance of regulating the activity in Argentina. According to Kulfas, the benefits will include: Health rights: supply of medical cannabis to ensure better access to health. ley cáñamo argentina. .” Employment: Generation of quality jobs.

Hemp 105

Hemp Research and Development Pharmaceutical Agriculture 105

Cannabis Law Report

SEPTEMBER 8, 2021

Flora will now have the ability to quickly and efficiently reference and manage information at its cultivation and extraction facility, collect and analyze data, derive insights to find cost efficiencies, and ensure accuracy. MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp.

Supply Chain 73

Supply Chain Pharmaceutical Seed-To-Sale Events 73

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? There are many different medical cannabis products. .

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

NOVEMBER 10, 2019

Europe Cannabis and Pain Management Devices on Cancer Pain market by key players: Cannabis Players: GW Pharmaceuticals. UNIMED PHARMACEUTICALS. Valeant Pharmaceuticals. About Us: MarketIntellica is a unique source of market research data for clients that comprise acclaimed SMEs, Chinese companies, private equity firms, and MNCs.

Pharmaceutical 45

Pharmaceutical Research and Development Data Business 45

The Cannigma

FEBRUARY 1, 2023

Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies. 36 Synthetic (pharmaceutical) cannabinoids and cancer Scientists did not rest when they learned that cannabis and cannabinoids may have anti cancer properties.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

The Cannigma

JUNE 14, 2021

We are allowed to cultivate, manufacture, research, analyze and distribute cannabis for scientifical, medical and pharmaceutical research. But beyond the relevance for research and the development of cannabis-based pharmaceutical drugs, Dr. Groff said the news could have very wide-ranging relevance for the legal status of cannabis as a whole.

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. About RYAH Group, Inc.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

JANUARY 6, 2022

An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. The FDA will likely refer to this data as it considers formal approval for psilocybin therapy and products. Threat to Patient Access in Oregon. Relationship Between Researchers and Private Industry. info@gl-lg.com ?

Access 52

Access Patients Research and Development Treatment 52

Cannabis Law Report

AUGUST 1, 2022

Love it or hate it, social media can be a powerful tool for education and data collection.

Education 52

Education Access Media Data 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

The Cannigma

FEBRUARY 11, 2021

One of the things she does is collect and analyze data about cannabis products and how patients with different medical conditions respond to them. All of that data is packaged into software doctors can use to manage their patients’ medical marijuana treatment. “I I know how to collect data. I know how to analyze data.

Wellness and Beauty 129

Wellness and Beauty Data Patients Medicine 129

Cannabis Law Report

JUNE 1, 2021

Given the size and scale of the study, RYAH has developed a custom software solution, using OAuth API-integration to protect the privacy of the participants in the study, with the goal of enabling a fully integrated, patient feedback and data collection capability. About RYAH Group, Inc. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 81

CBD Data Sleep Clinical Trials 81

Veriheal

JULY 12, 2021

Fortunately, congressional committees are fighting for medical cannabis access for veterans , and states are beginning to take measures to address their veterans , but what is the latest in research and what can one expect? Let’s find out. . Combat-Related PTSD is Slightly Different From PTSD .

Treatment 105

Treatment Sleep Clinical Trials Data 105

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. The industry also encourages the development of novel pharmaceuticals and treatments, creating opportunities for Maryland residents to access cutting-edge healthcare options.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

NOVEMBER 24, 2019

Building the bridge between brands and the marketplace through testing and the importance of good data. A need for data at all of these levels and data specific to product type drives more advanced methodology in the laboratories, often resulting in a better understanding of the matrix and more accurate data.

Business 95

Business Data Wellness and Beauty Safety 95

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. Additionally, there are misleading practices of “p-hacking” where researchers can manipulate data through different statistical tests (thanks to modern computer programs) looking for statistically significant findings.

Research and Development 112

Research and Development Data THC Clinical Trials 112

NewsMunchies

JULY 10, 2023

With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds major potential to increase the accessibility of drugs and to treat diseases and conditions. AI automation opens up the possibility of faster, cheaper pharmaceuticals. This, in turn, makes it possible to move fast without breaking things.

Treatment 58

Treatment Research and Development Pharmaceutical Microdosing 58

Cannabis Law Report

JULY 20, 2021

With our new psychedelic medicinal insurance solutions, business can access the necessary coverages to protect their business, attract qualified officers/directors, and bring new treatments to market.”. Rahn & Associates announced today that it launched new risk management solutions for the burgeoning psychedelic medicinal industry.

Medicine 75

Medicine Business Research and Development Chronic Pain 75

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

JANUARY 9, 2019

The largest cause of death in South Pacific females is cervical cancer; as there is little or no access to chemotherapy or radiotherapy. Tindall cites the positive strides GW Pharmaceuticals have made on overseas markets as the regulatory playbook to follow. It’s all about access and education,” said Tindall. “If

Therapy 85

Therapy Clinical Trials Treatment Medicine 85

CannaMD

NOVEMBER 6, 2019

And so, in light of America’s ongoing struggle with a sweeping opioid crisis of addiction and overdose deaths, it makes sense that there is a growing interest both among the public and the medical community in the possibilities of medical marijuana as an alternative to pharmaceuticals for pain management. percent, respectively.

Marijuana 88

Marijuana Patients Clinical Trials Data 88

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Google Translation.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

The Cannigma

AUGUST 5, 2022

When antidepressants were first introduced in the mid-20 th century, they were a breakthrough in pharmaceuticals. Most existing research does not support the use of THC in combating depression and there is very limited data for other cannabinoids.” But for thousands of people, these little pills aren’t enough.

Treatment 140

Treatment Research and Development Therapy Digestion 140

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

For example, many anti-anxiety pharmaceuticals are habit-forming, entail significant negative side effects, and can also cause physical problems such as diminished mobility or coordination. CBD seems to help the body’s natural endocannabinoid system return to normalcy and function better. CBD for Anxiety.

Treatment 112

Treatment Conditions CBD Clinical Trials 112

Veriheal

AUGUST 31, 2020

Essay Summary: Although doctors’ offices are full of pamphlets and flyers about mainstream pharmaceuticals in both English and Spanish, there is a lack of information for Hispanic patients seeking relief with cannabis and CBD. . Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” .

Research and Development 118

Research and Development Education Agriculture Patients 118

Project CBD

MAY 3, 2023

It’s noteworthy that much of this anecdotal data is supported by findings from preclinical research. Remember, the pharmaceutical model is “this medicine addresses this specific target.” There are pharmaceuticals for ADHD or behavioral issues, for example, which target this receptor. How easy is it to access CBG products?

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

JANUARY 17, 2022

The processes outlined in this patent application are positioned to enable scalable manufacturing because they require fewer synthetic steps than current methods, utilize cost effective and readily available starting materials, and leverage chemical manufacturing processes that are already standard practice in the pharmaceutical industry.

Research and Development 52

Research and Development Pharmaceutical Access Medicine 52

Cannabis Law Report

AUGUST 12, 2021

Since 2013, medicinal cannabis has been legalized in the Czech Republic due to the amendment to the Act on pharmaceuticals, otherwise known as Act No. With medical research indicating that using the plant provides significant medical benefits, the Czech Chamber of Deputies suggested a revision to the government’s Act on pharmaceuticals.

Legalization 59

Legalization Pharmaceutical Safety Extraction 59

CannaTech

FEBRUARY 25, 2019

Brainose is currently developing a pharmaceutical-grade cannabinoid-based therapy with a focus on pain management for FDA and CE approval in the U.S. Indorz : Indoor cannabis farming data solution that predicts, analyzes, and automates the grow process to maximize yield and quality. and Europe. Ag-tech and Growing Solutions.

Research and Development 85

Research and Development Hybrid Treatment Strains 85

Cannabis Law Report

JANUARY 14, 2022

Is it a natural response to the fact that recreational is supposedly on the way or a the report suggests it’s hard as a patient to access so therefore people are just giving up. The current lack of market growth reflects an unfortunate reality in Germany that patient access to medical cannabis is still quite low.

Pharmaceutical 52

Pharmaceutical Extraction Oil Patients 52

Cannabis Law Report

FEBRUARY 5, 2022

Review clinical protocols to ensure the collection of data needed for regulatory submissions. 5+ years’ experience in pharmaceutical industry preferably prescription medicines, narcotics, experimental drugs or products supplied via access schemes. SKILLS/QUALIFICATIONS. Minimum tertiary qualification in relevent field.

Medicine 52

Medicine Research and Development Clinical Trials Pharmaceutical 52

Cannabis Law Report

DECEMBER 15, 2021

Review clinical protocols to ensure the collection of data needed for regulatory submissions. 5+ years’ experience in pharmaceutical industry preferably prescription medicines, narcotics, experimental drugs or products supplied via access schemes. SKILLS/QUALIFICATIONS. Minimum tertiary qualification in relevent field.

Medicine 52

Medicine Research and Development Clinical Trials Pharmaceutical 52